One airway, one disease: An expert report into the true impact of hayfever and asthma
Developed by MEDA in partnership with Allergy UK
Dymista® is indicated for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient.
Adverse events should be reported.
Reporting forms and information can be found at www.mhra.gov.uk/yellowcard
Adverse events should also be reported to Meda's medical information line on: 01748 828810
UK/DYM/14/0070(1) Date of Prep: February 2017